TSMHT
JANX icon

Thurston Springer Miller Herd & Titak’s Janux Therapeutics JANX Stock Holding History

Thurston Springer Miller Herd & Titak’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-60
Closed -$828 – 1382
2025
Q4 		$828 Buy
+60
New +$1.41K ﹤0.01% 1307

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Thurston Springer Miller Herd & Titak's JANX Position: Q1 2026 in Review

Thurston Springer Miller Herd & Titak sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 60 shares — an estimated $828 sold.

Thurston Springer Miller Herd & Titak first reported a position in JANX in Q4 2025 and held it in 1 quarter. The position peaked at $828 in Q4 2025. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Thurston Springer Miller Herd & Titak reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Thurston Springer Miller Herd & Titak sold 60 Janux Therapeutics shares in Q1 2026, an estimated $828.
  • Thurston Springer Miller Herd & Titak first reported a position in Janux Therapeutics in Q4 2025 and held it in 1 quarter.
  • Thurston Springer Miller Herd & Titak's Janux Therapeutics position peaked at $828 in Q4 2025.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Thurston Springer Miller Herd & Titak's 13F filing for Q1 2026, filed 14 Apr 2026.